Phase 2a Study of VTX3232 in Parkinson's Disease

Completed · Phase 2

Conditions studied: Idiopathic Parkinson Disease

In brief

This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.

Key facts

Study ID
NCT06556173
Run by
Zomagen Biosciences Ltd.
People needed
11
Starts
2024-08-08
Expected to finish
2025-04-04
Last updated by the study team
2026-04-15

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.